1. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease 
Shounak Majumder, Sonmoon Mohapatra, Ryan J. Lennon, Guilherme Piovezani Ramos, Neil Postier, Ferga C. Gleeson, Michael J. Levy, Randall K. Pearson, Bret T. Petersen, Santhi Swaroop Vege, Suresh T. Chari, Mark D. Topazian, Thomas E. Witzig 
Clinical Gastroenterology and Hepatology 
Volume 16, Issue 12, Pages (December 2018)
DOI: /j.cgh
Copyright © 2018 AGA Institute Terms and Conditions

2. Figure 1
Kaplan–Meier curves showing the difference in relapse rates between groups after completion of rituximab induction therapy (time 0).
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

3. Figure 2
Kaplan–Meier curves showing the difference in relapse rates between groups after the last rituximab infusion (time 0).
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions

4. Figure 3
Kaplan–Meier curves showing the difference in relapse rates between patients with normal serum alkaline phosphatase (ALP) concentrations and patients with pretreatment alkaline phosphatase concentration increases that normalized after induction therapy or were persistently abnormal. RTX, rituximab.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2018 AGA Institute Terms and Conditions